Management of high blood pressure in: Perindopril/indapamide fixed-dose combination and the ADVANCE trial

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 10, 2010, Pages 1647-1657

  Ghiadoni, Lorenzo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Advance; Cardiovascular disease; Clinical trials; Diabetes; Diabetic complications; Gliclazide MR; Hypertension; Indapamide; Perindopril; Treatment

Indexed keywords

ATENOLOL; ENALAPRIL; GLICLAZIDE; INDAPAMIDE PLUS PERINDOPRIL; IRBESARTAN; LOSARTAN; PLACEBO; RAMIPRIL; TELMISARTAN;

ADULT; AGED; ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MICROALBUMINURIA; MICROANGIOPATHY; MORBIDITY; MORTALITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; INDAPAMIDE; MIDDLE AGED; PERINDOPRIL;

EID: 77953647822     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.491511     Document Type: Review

References (42)

1. International Diabetes Federation. Diabetes Atlas. 3rd edition. Brussels: International Diabetes Federation, 2006
2. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234
3. Lawes CM, Parag V, Bennett DA, et al. Asia Pacific Cohort Studies Collaboration. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care 2004;27:2836-2842
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13. Published erratum appears in BMJ 1999;318:29
5. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet 1998;352:837-853
6. Holman RR, Paul SK, Bethel A, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
7. Adler A, Stratton IM, Neil H, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes: UKPDS 36. Prospective observational study. BMJ 2000;321:412-419
8. MacMahon S. ADVANCE Management Committee. Study rationale and design of ADVANCE: Action in Diabetes and Vascular disease-Preterax and Diamicron MR Controlled Evaluation. Diabetologia 2001;44:1118-1120
9. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-838
10. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of angiotensin converting enzyme inhibitors, calcium antagonists and other blood pressure lowering drugs on mortality and major cardiovascular morbidity. Lancet 2000;356:1955-1964
11. Hansson L, Zanchetti A, Carruthers S, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-1762 (Pubitemid 28269185)
12. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-258
13. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153
14. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE Trial): a randomised controlled trial. Lancet 2007;370:829-840
15. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
16. de Galan BE, Perkovic V, Ninomiya T, et al. ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009;20:883-892
17. Zoungas S, de Galan B, Ninomiya T, et al. The combined effects of routine blood pressure lowering and intensive glucose on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from ADVANCE. Diabetes Care 2009;32:2068-2074
18. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585
19. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;25:421-426
20. Ninomiya T, Perkovic V, de Galan B, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in Diabetes. J Am Soc Nephrol 2009;20:1813-1821
21. Ninomiya T, Zoungas S, de Galan B, et al. The fixed combination of perindopril and indapamide has a greater effect on cardiovascular outcomes in patients with type 2 diabetes and albuminuria. ADVANCE Collaborative group [abstract]. J Hypertens 2009;27(Suppl 4):S179
22. Mann JFE, Schmieder RE, McQueen M, et al. on behalf of the ONTARGET Study Group. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-553
23. Mann JFE, Schmieder RE, Dyal L, et al. on behalf of the TRANSCEND RENAL Collaborative Group. Effect of telmisartan on renal outcomes. A randomized trial. Ann Intern Med 2009;151:1-10
24. Kengne AP, Czernichow S, Huxley R, et al. on behalf of the ADVANCE Collaborative Group. Blood pressure variables and cardiovascular risk. New findings from Advance. Hypertension 2009;54:399-404
25. Strippoli GF, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828-831
26. Brenner BM, Cooper ME, De Zeeuw D, et al. on behalf of the RENAAL Study Group. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
27. Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860
28. Parving HH, Lehnert H, Brochner-Mortensen J, et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878
29. Mourad J, Waeber B, Zannad F, et al. on behalf of STRATHE Trial Investigators. Comparison of different therapeutic strategies in hypertension: a low dose combination of perindopril/ indapamide versus a sequential monotherapy or a stepped care approach. J Hypertens 2004;22:2379-2386
30. Mancia G, DeBacker G, Dominiczak A, et al. Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007;25:1105-1187
31. Mogensen CE, Viberti G, Halimi S, et al. Preterax in Albuminuria Regression (PREMIER) Study Group. Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Preterax in Albuminuria Regression: PREMIER. Hypertension 2003;41:1063-1071
32. Dahlof B, Gosse P, Gueret P, et al.; on behalf of PICXEL Investigators. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005;23:2063-2070
33. De Luca N, Mallion JM, O'Rourke MF, et al. REASON Project. Regression of left ventricular mass in hypertensive patients treated with perindopril/ indapamide as a first-line combination. The REASON echocardiography study. Am J Hypertens 2004;17:660-667
34. Asmar RG, London GM, O'Rourke ME, et al. on behalf of REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflection with a very-low-dose perindopril/indapamide combination in hypertensive patients: a comparison with atenolol. Hypertension 2001;38:922-926
35. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588-2605
36. Ghiadoni L, Stea F, Bruno RM, et al. Central blood pressure, arterial stiffness, and wave reflection: new targets of treatment in essential hypertension. Curr Hypertens Rep 2009;11:190-196
37. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;356:2324-2325
38. Mourad JJ, Hanon O, Deverre JR, et al. Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/ diuretic therapy: a pilot PET study. J Renin Angiotensin Aldosterone Syst 2003;4:94-95
39. Neglia D, Fommei E, Ghione S, et al. Coronary microvascular dysfunction in hypertensive patients with left ventricular hypertrophy can be reversed by treatment with a combination of Perindopril/ indapamide [abstract]. Eur Heart J 2008;29:103
40. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005;111:363-368
41. Ghiadoni L, Kardasz I, Magagna A, et al. Fixed dose combination of perindopril and indapamide improves peripheral vascular function in essential hypertensive patients. Am J Hypertens 2009;22:506-512
42. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertension 2009;27:2121-2158